TTrialPathMatch Me to Trials
← Back to trials
RecruitingHypertension

Targeting Endoplasmic Reticulum Stress in Human Hypertension

Eligible age

18–80 yrs

Accepts

All genders

Locations

1 state

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

There is strong evidence suggesting that endoplasmic reticulum stress contributes to neurogenic and vascular hypertension in various animal models, however this has never been explored in humans. Therefore, this project will fill this gap by performing a single-blind, placebo-controlled trial in humans with hypertension.

Sponsor: University of North Texas Health Science Center

You may qualify if…

  • 1. 18 to 80 years of age
  • 2. No tobacco/nicotine use within preceding 6 months (e.g., cigarettes, chewing tobacco, nicotine gum or patches)
  • 3. Systolic blood pressure \<140 mmHg; diastolic blood pressure \<90 mmHg (obtained at the Screening and Familiarization Visit)
  • 4. Normal 12-lead ECG (obtained at the Screening and Familiarization Visit and reviewed by a board-certified physician)
  • 5. Normal clinical results from a medical exam reviewed by a board-certified physician (e.g., General Health Questionnaire obtained at the Screening and Familiarization Visit)
  • 6. Body mass index (BMI) \<35 unless athletic/muscular build; calculation = body weight (kg)/height (m2);
  • 7. Females only: documentation of a negative pregnancy test prior to the familiarization and experimental sessions unless post-menopausal

You may not qualify if…

  • 1. Not meeting the defined age criteria
  • 2. Body mass index (BMI) \>35 unless athletic/muscular build; calculation = body weight (kg)/height (m2)
  • 3. Any tobacco/nicotine use within the last 6 months (e.g., cigarettes, chewing tobacco, nicotine gum or patches)
  • 4. Positive pregnancy test
  • 5. Females with an erratic/irregular menstrual cycle
  • 6. Females who are breastfeeding
  • 7. Women who are prescribed a continually releasing hormonal contraceptive (e.g. NuvaRingTM or other hormone releasing vaginal rings, Depo Provera shot, or birth control implants such as Nexplanon)
  • 8. Subjects who weigh less than 80 lbs.

Where it's recruiting

Texas

Fort Worth

Source: ClinicalTrials.gov · NCT06025630 · last updated 2025-03-28